Bergen's new president is ex-Pracon head Roden: capitation pioneer returns after 20 years.
Executive Summary
BERGEN BRINGS BACK RODEN: "RESPECTED RELATIONSHIPS with leaders of the manufacturing and professional communities" form one of the prime attractions behind the choice of Donald Roden as president and CEO of the $8.5 bil. wholesaler/medical product supplier. During an early phase of his 25-year career in the pharmaceutical industry, Roden was part of a business development group at Bergen that experimented with running state Medicaid programs on an at-risk basis. Roden, 49, was with Bergen from 1974 to 1977 and served as a group VP for the subsidiary that ran the state contracts, Health Application Systems.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth